articlePubMedDec 3, 2004Closed access

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Vanderbilt University

PubMed
Indexed inpubmed

Abstract

Objectives

Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have been reported. Efavirenz is metabolized by cytochrome P4502B6 (CYP2B6). We investigated whether polymorphisms in CYP2B6, CYP3A4, CYP3A5, and MDR1 were associated with efavirenz central nervous system side effects and pharmacokinetics.

Design

Twenty-four week cohort from a randomized study.

Citation impact

629
total citations
FWCI
19.29
Percentile
100%
References
29
Citations per year

Authors

10

Topics & keywords

Keywords
  • Efavirenz
  • CYP2B6
  • Medicine
  • Internal medicine
  • Population
  • Gastroenterology
  • Immunology
  • CYP3A4
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.